Title: BioSentinel among 2010 “Wisconsin Companies to Watch”
Date: March 15, 2010
Link: http://www.biosentinelpharma.com/news.php
Article: MADISON – BioSentinel LLC has been recognized as one of nearly 30 “Wisconsin Companies to Watch,” a new awards program for second-stage companies.
The awards are presented by the Wisconsin Entrepreneurs’ Network with support from the Wisconsin Department of Commerce and the Division of Entrepreneurship and Economic Development at the UW-Extension in association with the Edward Lowe Foundation.
BioSentinel will be honored during the inaugural Wisconsin Companies to Watch gala on April 13, 2010, at the Monona Terrace Community and Convention Center in Madison.
BioSentinel was founded to develop tools for the detection of botulinum neurotoxins and to use those products for biodefense purposes. BioSentinel has ongoing collaborations with the U.S. Army Medical Institute of Chemical Defense, the U. S. Army Medical Research Institute of Infectious Diseases, the National Wildlife Health Center, the UW-Madison, the Wisconsin Security Research Consortium and private laboratories aimed at furthering botulinum neurotoxin research and eliminating the threat of botulinum neurotoxins as a bioterrorism weapon.
“BioSentinel is very deserving of this award,” said U.S. Rep. Tammy Baldwin, D-Wis., who has helped secure federal finding to support BioSentinel’s research. “The company’s work plays an important role in our national security and will help save the lives of our troops in the field and our people at home.”
“We are grateful to the Wisconsin Entrepreneurs’ Network for this recognition that will encourage us to fulfill the expectations of all those who have supported BioSentinel,” said Michael Cannon, senior managing partner for BioSentinel.
“BioSentinel is a WARF start-up company that has quickly developed a portfolio of products,” said Craig Heim, start-up licensing manager for the Wisconsin Alumni Research Foundation, the patent and licensing organization for UW-Madison. “This young company certainly has maintained our attention. It is clear the BioSentinel management team is focused on ensuring its unique technology will be put to work around the world to detect and defend against devastating botulinum toxins.”
“The Companies to Watch program recognizes companies at the crucial stage of growth where financial potential, concept and management have been established, and attracting talented workers, solid vendor relationships and access to peer learning are key components of future growth,” said Gayle Kugler of the Wisconsin Entrepreneurs’ Network. The Edward Lowe Foundation’s studies have shown second-stage companies are the ones that generate jobs and economic growth in their communities.
During 2005-2007, Wisconsin’s total resident companies included an average of more than 33,500 second-stage establishments, according to YourEconomy.org, an online resource of the Edward Lowe Foundation. Those second-stage companies employed more than 800,000 workers, or 36.7 percent of the jobs created by companies headquartered in the state.
Winners were selected by judges from the banking, economic development, entrepreneurial and angel communities. For a complete list of winners, visit: http://wenportal.org/newsroom/?Id=1104
Contacts:
Corporate: Julissa Salamanca, BioSentinel Pharmaceuticals LLC
Phone: 949-273-5409
email: jsalamanca@biosentinelpharma.com
Product Information: Dr. Bill Checovich
Phone: 608-334-1778
email: bchecovich@biosentinelpharma.com
Web site: http://www.biosentinelpharma.com
This press release should not be regarded as including projections or other forward-looking statements regarding future events or the future financial performance of BioSentinel, LLC. This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of BioSentinel, LLC, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioSentinel, LLC.
Title: WARF Start-up BioSentinel Launches Second Product for “Real Time” Detection of Deadly Botulinum Toxins
Date: January 12, 2010
Link: http://www.biosentinelpharma.com/news.php
Article: MADISON, WI – BioSentinel Pharmaceuticals, a start-up biodefense company founded in 2007 and based on University of Wisconsin-Madison technology licensed from the Wisconsin Alumni Research Foundation (WARF), has released its second product, BoTest™ B/D/F/G Botulinum Neurotoxin Kit (BoTest™ B/D/F/G). This new product provides research labs the first rapid and accurate assay for detecting the B, D, F and G serotypes of botulinum neurotoxin, the most poisonous substance known in the world. With the addition of this kit to the company’s first product, BoTest™ A/E, released last April, BioSentinel Pharmaceuticals now offers in vitro detection kits for six of the seven serotypes of botulinum neurotoxin.
BoTest™ B/D/F/G detects the proteolytic activity of botulinum strains by using a unique fluorescence-based substrate. This technique allows for real-time and endpoint detection of the toxins and offers an approximately 30-fold increase in sensitivity compared to other botulinum neurotoxin serotype B proteolytic assays on the market. It is the only assay on the market for the detection of serotypes D, F, and G.
“President Obama has directed the federal government to plan and prepare a rapid response of medical countermeasures to any biological attack on the American people,” said Congresswoman Tammy Baldwin (D-WI). “The key first step in such a response is rapid detection of a threat and BioSentinel’s new technology will serve to detect botulism toxins. BioSentinel’s work will help save the lives of our troops in the field and our people at home,” said Baldwin who secured federal funds to support BioSentinel’s research.”
The BoTest™ assays are intended for non-clinical research at academic, government, and pharmaceutical laboratories where an easy-to-use assay is required for drug-studies and discovery, quantification of toxin activity, and basic research studies.
“BioSentinel is rapidly reaching its goal of transforming basic research from the laboratory of Edwin Chapman at the University of Wisconsin into commercially viable products that will contribute to America’s ability to defend itself against bioterrorism,” said Michael Cannon, Senior Managing Partner, BPA and BioSentinel.
“BioSentinel’s ability to rapidly commercialize nascent university technologies is very encouraging,” said Craig Heim, start-up licensing manager for WARF, the patent and licensing organization for UW-Madison. “The company now has launched two innovative products in under three years of operation, which is unusually rapid and, more importantly, will contribute toward making the world a safer place.”
BioSentinel Pharmaceuticals LLC (BioSentinel) was founded to develop tools for the detection of botulinum neurotoxins and to use those tools for biodefense purposes. BioSentinel has ongoing collaborations with U.S. Army Medical Institute of Chemical Defense (USAMRICD), US Army Medical Research Institute of Infectious Disease (USAMRIID), USGS National Wildlife Health Center, UW-Madison, the Wisconsin Security Research Consortium and private laboratories aimed at furthering botulinum neurotoxin research and eliminating the threat of botulinum neurotoxins as a bioterrorism weapon. More information about BioSentinel, as well as BoTest™ and how it can be ordered, is available at: http://www.biosentinelpharma.com
This press release should not be regarded as including projections or other forward-looking statements regarding future events or the future financial performance of BioSentinel, LLC. This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of BioSentinel, LLC, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioSentinel, LLC.
Distributed through Wisconsin Technology Council News Services / www.wisconsintechnologycouncil.com
Contacts:
Julissa Salamanca, 949-273-5409, jsalamanca@biosentinelpharma.com
Dr. Bill Checovich, 608-334-1778, bchecovich@biosentinelpharma.com
Janet L. Kelly, 608.890-1491, jkelly@warf.org
Title: BioSentinel to present at 2009 IBRCC Conference
Date: October 14, 2009
Link: http://www.biosentinelpharma.com/news.php
Article:
MADISON – BioSentinel will be presenting at the 2009 IBRCC Conference in Alexandria, VA on October 18-23. Presentations and posters on BioSentinel’s latest assay technologies, including information on the upcoming BoTest™ B/D/F biochemical assay for the detection of BoNT B/D/F proteolytic activity and BoCell™, a cell-based assay for the detection of BoNTs.
Dr. Ward Tucker , Director of R&D will be giving an oral presentation entitled,
“In vitro and cell-based assays for the detection of botulinum neurotoxins.”
BioSentinel will have two poster presentations at the meeting:
“Development of cell-based assays for the detection of botulinum neurotoxin types A and B.”
“Optimization and qualification of in vitro FRET reporters for the detection of botulinum neurotoxins serotypes A, B, D, E, and F.”
BioSentinel Pharmaceuticals LLC (BioSentinel) is a start-up biodefense company founded to develop tools for the detection of botulinum neurotoxins and use those tools for biodefense purposes. Founded in partnership with Wisconsin Alumni Research Foundation, BioSentinel began operations in June 2007. BioSentinel has ongoing collaborations with U.S. Army Medical Institute of Chemical Defense (USAMRICD), National Wildlife Health Center, the UW-Madison, the Wisconsin Security Research Consortium and private laboratories aimed at furthering botulinum neurotoxin research and eliminating the threat of botulinum neurotoxins as a bioterrorism weapon.
More information about BoTest™ and how it can be ordered can be found on line at www.biosentinelpharma.com.
Contacts:
Julissa Salamanca, BioSentinel Pharmaceuticals LLC
949-273-5409
jsalamanca@biosentinelpharma.com
Web site: http://www.biosentinelpharma.com
Title: BioSentinel releases “real-time” detection test for deadly strains of botulinum toxins
Date: April 28, 2009
Link: http://www.biosentinelpharma.com/news.php
Article:
MADISON – A breakthrough test to rapidly and accurately detect small amounts of the most deadly strains of botulinum toxin has been released by BioSentinel Pharmaceuticals LLC, a Madison-based company.
The company’s new “BoTest”™ offers nearly a 300-fold increase in sensitivity compared to other botulinum neurotoxin protein-based assays on the market. It can detect molecular-picomolar level amounts of the toxins within minutes.
“BioSentinel’s groundbreaking assay will help protect our citizens at home and our troops in the field, and the expanded research opportunities hold much promise for future health care benefits,” said U.S. Rep. Tammy Baldwin, D-Wis., who secured federal funds to help support BioSentinel’s research.
The BoTest™ assay (nonclinical, research use only) is intended for academic, government and pharmaceutical laboratories where an easy-to-use assay is required for drug-studies and discovery, quantification of toxin activity, and basic research studies.
“Reliable, sensitive, and robust assays for the detection of botulinum neurotoxins are critically needed in the marketplace,” said Ben Lap, CEO of BioSentinel Pharmaceuticals. “In the past, researchers in biodefense, basic research, and pharmaceuticals have relied on assays that were expensive or lacking the necessary throughput. We believe the introduction of BoTest™ to the market will allow researchers to perform experiments not previously possible and accelerate their research.”
BioSentinel Pharmaceuticals LLC (BioSentinel) is a start-up biodefense company founded to develop tools for the detection of botulinum neurotoxins and use those tools for biodefense purposes. Founded in partnership with Wisconsin Alumni Research Foundation, BioSentinel began operations in June 2007. BioSentinel has ongoing collaborations with U.S. Army Medical Institute of Chemical Defense (USAMRICD), National Wildlife Health Center, the UW-Madison, the Wisconsin Security Research Consortium and private laboratories aimed at furthering botulinum neurotoxin research and eliminating the threat of botulinum neurotoxins as a bioterrorism weapon.
“A start-up company’s first commercial product launch is an exciting achievement,” said Craig Heim, start-up licensing manager for WARF, which is the patent and licensing organization for the UW-Madison. “BioSentinel’s accomplishment is even more impressive in the current economic climate, and I am especially proud to see a university start-up company fuel Wisconsin’s economy and make the world a safer place.”
BoTest™ is designed to detect the proteolytic activity of botulinum neurotoxin serotypes A and E using a unique fluorescence-based substrate that allows for “real-time” readout of picomolar amounts of toxin activity. BoTestTM is fast, easy to perform and the most sensitive product of its kind in the market.
More information about BoTest™ and how it can be ordered can be found on line at www.biosentinelpharma.com.
Distributed through Wisconsin Technology Council News Services / www.wisconsintechnologycouncil.com
Contacts:
Julissa Salamanca, BioSentinel Pharmaceuticals LLC
949-273-5409
jsalamanca@biosentinelpharma.com
Web site: http://www.biosentinelpharma.com
©2009 BioSentinel Pharmaceuticals - All Rights Reserved - Terms & Conditions
